LSV Asset Management
CPRX

LSV Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

LSV Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Sell
325,200
-284,300
-47% -$8.39M 0.02% 434
2026
Q1 		$15.1M Buy
609,500
+69,600
+13% +$1.66M 0.03% 349
2025
Q4 		$12.6M Sell
539,900
-12,500
-2% -$278K 0.03% 364
2025
Q3 		$10.9M Sell
552,400
-25,300
-4% -$520K 0.02% 394
2025
Q2 		$12.5M Sell
577,700
-126,102
-18% -$2.98M 0.03% 362
2025
Q1 		$17.1M Sell
703,802
-73,322
-9% -$1.65M 0.04% 329
2024
Q4 		$16.2M Sell
777,124
-174,200
-18% -$3.74M 0.04% 344
2024
Q3 		$18.9M Buy
951,324
+77,424
+9% +$1.44M 0.04% 322
2024
Q2 		$13.5M Sell
873,900
-22,100
-2% -$344K 0.03% 393
2024
Q1 		$14.3M Sell
896,000
-334,700
-27% -$5.04M 0.03% 388
2023
Q4 		$20.7M Sell
1,230,700
-10,069
-0.8% -$138K 0.05% 332
2023
Q3 		$14.5M Buy
1,240,769
+253,100
+26% +$3.39M 0.03% 375
2023
Q2 		$13.3M Buy
987,669
+29,869
+3% +$430K 0.03% 384
2023
Q1 		$15.9M Sell
957,800
-59,671
-6% -$984K 0.04% 342
2022
Q4 		$18.9M Sell
1,017,471
-2,377,018
-70% -$36.6M 0.04% 314
2022
Q3 		$43.6M Sell
3,394,489
-635,188
-16% -$7.53M 0.1% 219
2022
Q2 		$28.2M Buy
4,029,677
+326,405
+9% +$2.39M 0.06% 262
2022
Q1 		$30.7M Sell
3,703,272
-348,797
-9% -$2.47M 0.06% 282
2021
Q4 		$27.4M Sell
4,052,069
-1,207,636
-23% -$7.94M 0.05% 315
2021
Q3 		$27.9M Buy
5,259,705
+1,019,389
+24% +$5.57M 0.05% 311
2021
Q2 		$24.4M Buy
4,240,316
+2,829,579
+201% +$14.6M 0.04% 350
2021
Q1 		$6.5M Sell
1,410,737
-82,400
-6% -$327K 0.01% 524
2020
Q4 		$4.99M Sell
1,493,137
-101,100
-6% -$340K 0.01% 558
2020
Q3 		$4.73M Buy
1,594,237
+1,424,544
+839% +$5.57M 0.01% 543
2020
Q2 		$783K Buy
+169,693
New +$762K ﹤0.01% 780

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LSV Asset Management's CPRX Position: Q2 2026 in Review

LSV Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 47% in Q2 2026, selling an estimated $8.39M and leaving 325,200 shares worth $10.2M. The position accounts for 0.02% of the portfolio, ranked #434.

LSV Asset Management first reported a position in CPRX in Q2 2020 and has held it in 25 quarters since. The position peaked at $43.6M in Q3 2022. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • LSV Asset Management held 325,200 shares of Catalyst Pharmaceutical worth $10.2M as of Q2 2026.
  • LSV Asset Management sold 284,300 Catalyst Pharmaceutical shares in Q2 2026, an estimated $8.39M.
  • Catalyst Pharmaceutical made up 0.02% of LSV Asset Management's portfolio in Q2 2026, its #434 holding.
  • LSV Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2020 and has held it in 25 quarters since.
  • LSV Asset Management's Catalyst Pharmaceutical position peaked at $43.6M in Q3 2022.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on LSV Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.